HCA Warning, Leqembi Shift, Insulin PBM, ICER Advice

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning, especially that HCA warning.

MarcusSame here. We're looking at HCA's profit warning signaling access erosion in US healthcare. Then subcutaneous Leqembi approval reshaping Alzheimer's value narratives. The FTC settlement with CVS Caremark over insulin pricing practices. And ICER's expansion of early-phase scientific advice.

SaraThat second one is interesting to me — the budget impact question there is one the field hasn't fully worked out yet. Convenience benefits rarely translate to clear cost offsets.

MarcusExactly. Let's get into it.

MarcusHCA issued a profit warning citing access challenges in US healthcare. What strikes me is the signal this sends about the sustainability of current access models for innovative therapies.

SaraThat's a key point. From the payer side, I wonder if that's the full picture though? We've seen similar warnings before, but what's different now is the pressure on hospital margins from high-cost drugs and the shift to value-based contracts.

MarcusExactly, and the timing is critical. With the IRA implementation ongoing and the Part D redesign, HCA's warning may reflect the operational friction of these policies. But I'd push back slightly — is it only about drug costs, or is there a broader operational efficiency issue at play?

SaraThat's fair, though I think payers would see it as a symptom of a larger system stress. The part that gives me pause is the lack of clarity on how hospital systems are adapting their formularies and contracting strategies in response. This could have downstream effects on drug pricing negotiations.

MarcusThat connects to something I keep coming back to: the patient perspective. If hospital systems are struggling, how does that impact patient access? This is one of those stories where the commercial and patient access narratives are colliding.

SaraRight, and from the payer side, the opportunity cost here is significant. Resources diverted to managing high-cost drugs could mean less investment in other areas. The HCA warning is a bellwether for the entire system.

SaraThe FDA approved subcutaneous Leqembi, which is a big deal for Alzheimer's treatment. What's striking here is the route of administration change — it could significantly impact patient adherence and real-world outcomes.

MarcusAbsolutely, and from an evidence strategy perspective, this approval opens up new questions for HEOR teams. The pivotal trial was intravenous, so now we need to generate real-world evidence that subcutaneous delivery maintains efficacy and improves quality of life. I wonder if that's the full picture though? The FDA approval was based on bridging data, but the long-term evidence generation is critical.

SaraThat's one read — I'd frame it slightly differently. The budget impact question here is one the field hasn't fully worked out yet. If adherence improves, that could offset some of the cost concerns, but we need to see the data. The part that gives me pause is the potential for increased utilization if administration becomes more convenient. That could strain Part D budgets.

MarcusWhat strikes me is the precedent this sets. If subcutaneous administration becomes the norm, it could force a reevaluation of how we value convenience in HTA frameworks. This is one of those stories where the innovation in delivery is as important as the drug itself.

SaraRight, and from the payer side, the challenge will be distinguishing between the clinical benefit and the operational benefit. The HEOR community will need to develop new methods to capture that value. Honestly, this one caught me off guard — the implications are broader than just another Alzheimer's drug.

MarcusExactly. We'll be watching the first real-world evidence studies and how payers incorporate this into their value assessments.

MarcusThe FTC settled with CVS Caremark over insulin pricing practices. This is significant because it targets the pharmacy benefit manager (PBM) role in the insulin supply chain, which has been a black box for years.

SaraThat's fair, though I think payers would see it differently. The part that gives me pause is whether this settlement will actually reduce patient costs or just shift them. We've seen similar interventions before, but the structural issues in PBM contracting remain. The FTC's focus on retroactive rebates is interesting, but will it lead to sustainable change?

MarcusI'd push back slightly on that. The fact that the FTC is acting at all signals a regulatory shift. This could be a precedent for other high-cost drugs. But what's striking here is the lack of transparency in the PBM model — the settlement forces some level of disclosure. That's a win for evidence-based decision making.

SaraThat connects to something I keep coming back to: the opportunity cost. If PBMs are using their market power to extract rebates, how does that impact the overall system? The settlement might address one piece, but the broader question of PBM influence remains. This is one of those stories where the commercial dynamics are as important as the policy.

MarcusAbsolutely. We'll be watching how other PBMs respond and whether this leads to more competitive pricing for insulin and other biologics.

SaraAnd from the patient perspective, any reduction in out-of-pocket costs is positive, but the real test is whether the savings are passed through.

SaraICER is expanding its early-phase scientific advice program. This is a big move because it's shifting the timing of value assessment earlier in development, which could de-risk HEOR strategy for companies.

MarcusExactly, and from the industry side, this is a welcome development. Getting early input on evidence generation can prevent costly late-stage surprises. But what strikes me is the operational challenge for ICER — how do they maintain methodological rigor when the data is so limited? I wonder if that's the full picture though?

SaraThat's one read — I'd frame it slightly differently. The budget impact here is one the field hasn't fully worked out yet. If more companies engage early, it could increase ICER's workload and potentially delay assessments. The part that gives me pause is the potential for misaligned expectations. Companies might see this as a green light, but payers will still require robust evidence.

MarcusThat's a fair point. But I think the key is the signal it sends about the evolution of HTA. By engaging earlier, we might see more efficient evidence generation. This is one of those stories where the collaboration between industry and HTA bodies could lead to better outcomes for patients.

SaraRight, and from the payer side, the opportunity is to influence trial design and endpoints early on. But the risk is that early advice becomes a de facto approval, which it shouldn't be. The HEOR community will need to navigate this carefully.

MarcusAbsolutely. We'll be watching how this program evolves and whether it becomes a standard part of development pathways.

SaraA lot to think about today. I'll be watching how HCA's profit warning influences hospital system strategies and whether it leads to any changes in drug access policies.

MarcusSame — and for me the thread running through today is the increasing pressure on US healthcare systems to balance innovation with sustainability. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

Sara"Thanks for listening — see you tomorrow."

Marcus"Back tomorrow on Access Brief. Show notes at outcomes-analytica.no."